Skip to main content
Midas Edge

Pulmonx Corp

For the period ended Sep 30, 2024. Filed Nov 1, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 1, 2024

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount
Balances at January 1, 202438,516,383$39$526,797$2,640$(411,161)$118,315
Issuance of common stock upon vesting of restricted stock units177,610—————
Issuance of common stock upon exercise of stock options28,116—57——57
Issuance of shares pursuant to employee stock purchase plan90,066—808——808
Stock-based compensation expense——5,744——5,744
Currency translation adjustment———(549)—(549)
Change in unrealized losses on marketable securities———(128)—(128)
Net loss————(13,749)(13,749)
Balances at March 31, 202438,812,17539533,4061,963(424,910)110,498
Issuance of common stock upon vesting of restricted stock units328,336—————
Issuance of common stock upon exercise of stock options11,350—22——22
Stock-based compensation expense——5,980——5,980
Currency translation adjustment———40—40
Change in unrealized losses on marketable securities———(30)—(30)
Net loss————(15,326)(15,326)
Balances at June 30, 202439,151,86139539,4081,973(440,236)101,184
Issuance of common stock upon vesting of restricted stock units239,518—————
Issuance of common stock upon exercise of stock options12,625—29——29
Issuance of shares pursuant to employee stock purchase plan83,875—431——431
Stock-based compensation expense——5,864——5,864
Currency translation adjustment———412—412
Change in unrealized gains on marketable securities———149—149
Net loss————(14,144)(14,144)
Balances at September 30, 202439,487,879$39$545,732$2,534$(454,380)$93,925
Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount
Balances at January 1, 202337,555,565$38$502,712$1,575$(350,318)$154,007
Issuance of common stock upon vesting of restricted stock units66,895—————
Issuance of common stock upon exercise of stock options23,006—46——46
Issuance of shares pursuant to employee stock purchase plan85,210—676——676
Change in shares subject to repurchase——56——56
Stock-based compensation expense——4,764——4,764
Currency translation adjustment———72—72
Change in unrealized gains on marketable securities———173—173
Net loss————(15,860)(15,860)
Balances at March 31, 202337,730,67638508,2541,820(366,178)143,934
Issuance of common stock upon vesting of restricted stock units222,598—————
Issuance of common stock upon exercise of stock options63,503—139——139
Change in shares subject to repurchase——47——47
Repurchase of early exercised common stock options(106)—————
Stock-based compensation expense——5,891——5,891
Currency translation adjustment———170—170
Change in unrealized losses on marketable securities———(34)—(34)
Net loss————(16,195)(16,195)
Balances at June 30, 202338,016,67138514,3311,956(382,373)133,952
Issuance of common stock upon vesting of restricted stock units193,954—————
Issuance of common stock upon exercise of stock options25,189—62——62
Issuance of shares pursuant to employee stock purchase plan65,632—508——508
Change in shares subject to repurchase——33——33
Stock-based compensation expense——6,100——6,100
Currency translation adjustment———(12)—(12)
Net loss————(14,900)(14,900)
Balances at September 30, 202338,301,446$38$521,034$1,944$(397,273)$125,743
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.